RUTHERFORD, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced the presentation of results from two Cancer Genetics-led research studies at the 2015 Association for Molecular Pathology Meeting, taking place in Austin, Texas on November 5th-7th. The first study, entitled, “A Multi-Platform Approach for the Detection of Mutations in 54 genes with Relevance to Myeloid Neoplasms in a Clinical Laboratory Setting,” was led by Dr. Jane Houldsworth, Ph.D., Vice President of Research and Development at CGI. The aim of the study was to analyze mutations in 54 genes with relevance to MDS, AML, and MPN using a multi-platform approach, which combined NGS, Sanger sequencing, and PCR fragment analysis.
There are approximately 54,000 newly diagnosed cases of myeloid cancers in the U.S. each year – 19,000 cases of AML, 15,000 cases of MDS, and 20,000 cases of MPN. While traditional methods for diagnosis and patient stratification are time-consuming and expensive, new options such as CGI’s Focus::Myeloid™ test, deliver comprehensive genomic assessments in a single test for accurate, economical, and rapid profiling of a patient’s tumor.
The second study, is titled, “Systematic Analysis of Recurrent Copy Number Variants in Diffuse Large B-cell Lymphomas". The goal of the study was to identify novel, molecular prognostic biomarkers in diffuse large B-cell lymphoma patients and to integrate these with existing prognostic biomarkers, analyzed for 50 predetermined common copy number variations.
Details for the poster presentation are the following:
|Event Name:||Association for Molecular Pathology, Austin, TX|
|Date and Time:||November 5th-7th, 2015|
|Poster #H52:||A Multi-Platform Approach for the Detection of Mutations in 54 genes with Relevance to Myeloid Neoplasms in a Clinical Laboratory Setting|
|Poster #H30:||Systematic Analysis of Recurrent Copy Number Variants in Diffuse Large B-cell Lymphomas|
|The poster abstracts can be viewed online through on The Journal of Molecular Diagnostics website.|
|Cancer Genetics Booth:||1815|
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended June 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Media Contact: Cancer Genetics, Inc. Marie-Agnes Patrone-Michellod, PhD. Tel: 201.528.9200 Email: email@example.com
Source:Cancer Genetics, Inc.